Figure 2.

Tumor and inflammation score of p47phox−/− and wild-type (WT) mice treated with or w/o toll-like receptor 9 ligand CpG. (A) Tumor score and (B) inflammation score of p47phox−/− and WT mice, determined by colonoscopic examination. (C) Tumor score and (D) inflammation score of p47phox−/− and WT mice, weekly treated with 25 µg CpG2216. (E,F) Weight development of mice treated w/o (E) and with CpG (F) during and after the third DSS cycle as percentage of starting weight. The DSS cycle is marked in gray. (A–F) Results are mean ± SEM of three independent experiments with at least seven mice per group. Statistical significance is indicated (*P < 0.05; **P < 0.01; ***P < 0.001).